PMID- 16775507
OWN - NLM
STAT- MEDLINE
DCOM- 20061106
LR  - 20161124
IS  - 0160-2446 (Print)
IS  - 0160-2446 (Linking)
VI  - 47
IP  - 5
DP  - 2006 May
TI  - Changes in atrium and thoracic aorta reactivity to adenosinergic and adrenergic 
      agonists in experimental hyperhomocysteinemia.
PG  - 673-9
AB  - We prepared diet-induced hyperhomocysteinemia (hHcy) in adult male Wistar rats 
      and investigated the effects of hHcy on the adenosinergic and adrenergic 
      responses in vitro and in vivo. The responsiveness of right atria from hHcy rats 
      to the negative chronotropic effects of adenosine (Ado) was found to be 
      significantly greater in hHcy rats than in controls. The pD2 value and maximum 
      effect of Ado were significantly increased in 12-week hHcy right atria when 
      compared with those from age-matched controls. The vasodilatory effect of Ado on 
      rat thoracic aorta was also increased in hHcy rats. In the presence of 
      dipyridamole, an Ado uptake inhibitor, the negative chronotropic and vasodilatory 
      effects of Ado were significantly potentiated in the hHcy rats much more than in 
      the control rats. In anesthetized rats, Ado and dipyridamole, given as a rapid 
      bolus into the femoral artery, led to reduction in mean blood pressure and heart 
      rate. This effect was significantly pronounced in hHcy rats when compared with 
      control animals. Otherwise, hHcy atria were found to have increased 
      responsiveness to the positive chronotropic response to isoproterenol, an 
      beta-adrenoceptor agonist. However, there were no significant differences between 
      two groups in the vasoconstrictor effects to phenylephrine, an alpha-adrenoceptor 
      agonist. On the basis of these results, we concluded that hHcy rats were 
      significantly more sensitive to the negative chronotropic and vasorelaxant 
      effects of Ado, possibly because of accelerated cellular Ado uptake and/or a 
      change in Ado receptor-G protein system. This change may be related with the 
      increased responsiveness to beta-adrenergic agonists in hHcy rats, and might 
      contribute to the harmful cardiac effects of hHcy.
FAU - Tasatargil, Arda
AU  - Tasatargil A
AD  - Department of Pharmacology, Akdeniz University Medical Faculty, Medical School, 
      Akdeniz University, 07059, Antalya, Turkey. ardatas@akdeniz.edu.tr
FAU - Sadan, Gulay
AU  - Sadan G
FAU - Karasu, Edibe
AU  - Karasu E
FAU - Ozdem, Sebahat
AU  - Ozdem S
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Cardiovasc Pharmacol
JT  - Journal of cardiovascular pharmacology
JID - 7902492
RN  - 0 (Adrenergic alpha-Agonists)
RN  - 0 (Adrenergic beta-Agonists)
RN  - 0 (Purinergic P1 Receptor Agonists)
RN  - 0 (Purinergic P1 Receptor Antagonists)
RN  - 0LVT1QZ0BA (Homocysteine)
RN  - 1WS297W6MV (Phenylephrine)
RN  - 64ALC7F90C (Dipyridamole)
RN  - AE28F7PNPL (Methionine)
RN  - C137DTR5RG (Theophylline)
RN  - E6M543P3BL (8-phenyltheophylline)
RN  - K72T3FS567 (Adenosine)
RN  - L628TT009W (Isoproterenol)
SB  - IM
MH  - Adenosine/pharmacology
MH  - Adrenergic alpha-Agonists/*pharmacology
MH  - Adrenergic beta-Agonists/*pharmacology
MH  - Animals
MH  - Aorta, Thoracic/*drug effects/physiopathology
MH  - Blood Pressure/drug effects
MH  - Dipyridamole/pharmacology
MH  - Heart Atria/*drug effects
MH  - Heart Rate/drug effects
MH  - Homocysteine/blood
MH  - Hyperhomocysteinemia/chemically induced/*physiopathology
MH  - Isoproterenol/pharmacology
MH  - Male
MH  - Methionine/pharmacology
MH  - Phenylephrine/pharmacology
MH  - *Purinergic P1 Receptor Agonists
MH  - Purinergic P1 Receptor Antagonists
MH  - Rats
MH  - Rats, Wistar
MH  - Theophylline/analogs & derivatives/pharmacology
MH  - Vasoconstriction/drug effects
MH  - Vasodilation/drug effects
EDAT- 2006/06/16 09:00
MHDA- 2006/11/07 09:00
CRDT- 2006/06/16 09:00
PHST- 2006/06/16 09:00 [pubmed]
PHST- 2006/11/07 09:00 [medline]
PHST- 2006/06/16 09:00 [entrez]
AID - 00005344-200605000-00008 [pii]
AID - 10.1097/01.fjc.0000211756.31820.17 [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol. 2006 May;47(5):673-9. doi: 
      10.1097/01.fjc.0000211756.31820.17.